Survodutide: The Glucagon/GLP-1 Dual Agonist with 16.6% Weight Loss

The next wave of obesity drugs is no longer about adding more GLP-1. It's about pairing GLP-1 with a second hormonal axis that GLP-1 alone cannot reach. Eli Lilly's tirzepatide layered on GIP. Retatrutide layered on glucagon and GIP. Boehringer Ingelheim and Zealand Pharma chose a different combination — survodutide (BI 456906), a once-weekly subcutaneous peptide that activates the GLP-1 receptor and the glucagon receptor simultaneously. After a positive Phase 2 in obesity, a positive Phase 2 in MASH, and now a Phase 3 SYNCHRONIZE-1 readout showing 16.6% sustained weight loss at 76 weeks, survodutide is the most clinically advanced glucagon/GLP-1 co-agonist in development.

Evidence: "Adults living with obesity or overweight without type 2 diabetes treated with survodutide experienced sustained weight loss of up to an average of 16.6% after 76 weeks, compared with 3.2% in the placebo arm." — Boehringer Ingelheim SYNCHRONIZE-1 topline results, April 2026.

The full SYNCHRONIZE-1 manuscript will be presented at the American Diabetes Association Scientific Sessions in June 2026, with the broader Phase 3 program — SYNCHRONIZE-2 in adults with type 2 diabetes and SYNCHRONIZE-CVOT in cardiovascular high-risk populations — reading out over the following 18 months.

Why a Glucagon Agonist Helps You Lose Weight

If your introduction to obesity pharmacology came through semaglutide or tirzepatide, the inclusion of glucagon in a weight-loss drug may sound counterintuitive. Glucagon is the hormone that drives hepatic glucose output during fasting — exactly the signal you would expect to make blood sugar worse. But glucagon does something else that has been underexploited in the obesity field for decades: it increases resting energy expenditure and promotes hepatic fat oxidation.

Evidence: "Glucagon receptor activation drives hepatic lipid oxidation and increases energy expenditure, while GLP-1 receptor activation reduces food intake; the combination produces additive weight loss in preclinical models with neutralization of glucagon's hyperglycemic effect by concurrent GLP-1 signaling." — Zimmermann T, et al. Molecular Metabolism. 2022. DOI: 10.1016/j.molmet.2022.101633

The biological logic of dual agonism is that GLP-1 reduces caloric intake while glucagon raises caloric output, and the two effects together avoid the metabolic adaptation problem that limits GLP-1 monotherapy. GLP-1's incretin effect on insulin release is also dose-protective — it blunts the hyperglycemic risk that pure glucagon agonism would otherwise carry. Survodutide is engineered with a peptide backbone derived from oxyntomodulin, the natural gut hormone that activates both receptors, with a fatty-acid side chain that extends its half-life enough for once-weekly dosing.

How survodutide compares mechanistically

Drug	Receptor activity	Phase 3 mean weight loss	Status
Semaglutide 2.4 mg (Wegovy)	GLP-1	~14.9% at 68 wks	Approved
Tirzepatide 15 mg (Zepbound)	GLP-1 + GIP	~20.9% at 72 wks	Approved
Retatrutide 12 mg	GLP-1 + GIP + glucagon	~24.2% at 48 wks (Ph 2)	Phase 3
Survodutide 6.0 mg	GLP-1 + glucagon	16.6% at 76 wks	Phase 3 readout
CagriSema 2.4/2.4 mg	GLP-1 + amylin	~22.7% at 68 wks	NDA filed

Two mechanism notes deserve emphasis. Survodutide and retatrutide both activate the glucagon receptor, but retatrutide also engages GIP, which contributes additional satiety and adipocyte-level effects. Survodutide therefore tests a cleaner version of the GLP-1 + glucagon hypothesis without GIP confounding — useful scientifically, even if the magnitude of weight loss appears smaller than retatrutide's.

Phase 2 in Obesity: 18.7% in High-Dose Completers

The dose-finding Phase 2 obesity trial enrolled 387 adults with BMI ≥27 kg/m² and no type 2 diabetes across 43 centers in 12 countries. Participants were randomized to weekly subcutaneous survodutide at 0.6, 2.4, 3.6, or 4.8 mg, or placebo, for 46 weeks (20 weeks of dose escalation followed by 26 weeks of maintenance).

Evidence: "Mean bodyweight changes from baseline to week 46 were −6.2% (0.6 mg), −12.5% (2.4 mg), −13.2% (3.6 mg), and −14.9% (4.8 mg) with survodutide, compared with −2.8% with placebo. Among participants who reached and maintained the target dose of 4.8 mg, mean weight loss was 18.7%." — le Roux CW, et al. Lancet Diabetes & Endocrinology. 2024. DOI: 10.1016/S2213-8587(23)00356-X

A clean dose-response curve, a placebo arm performing as expected, and an 18.7% per-protocol weight-loss signal in completers were enough to advance the molecule to Phase 3. The trial also met two thresholds that obesity regulators care about: 82.8% of patients on the 4.8 mg dose achieved ≥5% weight loss (versus 26% on placebo), and 54.7% achieved ≥15% loss — a benchmark previously seen mostly with tirzepatide. Up to 40% of participants on the two highest doses achieved ≥20% weight loss, which is comparable to early Phase 2 signals from retatrutide.

Body composition: predominantly fat

A recurring concern with high-magnitude weight loss is the fraction that comes from lean mass — a problem we cover in detail in our review of GLP-1 muscle preservation. Survodutide's preliminary body-composition signal looks favorable: Boehringer Ingelheim's SYNCHRONIZE-1 readout reports that the weight reduction "was driven predominantly by loss of fat tissue, with lean mass contributing only a small proportion." This is consistent with the preclinical pharmacology data showing glucagon receptor activation preferentially mobilizes hepatic and visceral fat stores, but full DEXA-based body-composition analyses from the Phase 3 program are still pending peer-reviewed publication.

SYNCHRONIZE-1: The Phase 3 Headline

SYNCHRONIZE-1 is a 76-week, double-blind, randomized, placebo-controlled trial enrolling 725 adults with obesity or overweight without type 2 diabetes across 14 countries. Participants were randomized to once-weekly subcutaneous survodutide (titrated to 3.6 mg or 6.0 mg) or matching placebo, on top of standardized lifestyle counseling. The primary endpoints were percent change in body weight at week 76 and the proportion of participants achieving ≥5% weight loss.

Evidence: "SYNCHRONIZE-1 enrolled participants with mean age 47.1 years, BMI 37.9 kg/m², and waist circumference 115.2 cm; 59.4% were female, with 47.3% from North America, 21.0% from Europe, and 20.0% from East Asia. Common obesity-related complications included hypertension (40.0%), dyslipidemia (33.7%), and prediabetes (30.2%)." — le Roux CW, et al. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70196

The topline numbers from Boehringer Ingelheim's April 2026 announcement:

−16.6% mean weight loss with survodutide at 76 weeks vs. −3.2% with placebo (p < 0.0001)
85.1% of participants on survodutide achieved ≥5% weight loss vs. 38.8% on placebo
Statistically significant reductions in waist circumference, systolic blood pressure, and lipid panel
Both primary endpoints and the key secondary endpoint on waist circumference met

The 16.6% mean number represents the treatment-policy estimand (everyone randomized, including discontinuers), which is the conservative regulatory yardstick. Trial-product estimand numbers — the "if you stay on the drug, here is what happens" view — typically run two to three percentage points higher and will be in the published manuscript.

How survodutide stacks up against approved obesity drugs

For comparison: the STEP-1 trial of semaglutide 2.4 mg in non-diabetic adults reported a 14.9% mean weight loss at 68 weeks, and SURMOUNT-1 with tirzepatide 15 mg reported 20.9% at 72 weeks. Survodutide's 16.6% places it cleanly between Wegovy and Zepbound in efficacy magnitude, while offering a mechanism (glucagon co-agonism) that neither drug provides.

Evidence: "Once-weekly subcutaneous semaglutide at a dose of 2.4 mg plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight (mean change, −14.9% at 68 weeks)." — Wilding JPH, et al. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183

Evidence: "In adults with obesity, once-weekly tirzepatide at a dose of 15 mg produced a mean change in body weight of −20.9% at 72 weeks." — Jastreboff AM, et al. New England Journal of Medicine. 2022. DOI: 10.1056/NEJMoa2206038

Phase 2 in MASH: A Liver Trial With Outsized Implications

Outside the obesity Phase 3 program, survodutide has produced one of the strongest MASH (metabolic dysfunction-associated steatohepatitis) data sets in the field — a relevant secondary indication given how many people with obesity also live with fatty liver disease. The 48-week NEJM Phase 2 trial randomized 295 adults with biopsy-confirmed MASH and fibrosis stage F1–F3 to weekly survodutide at 2.4, 4.8, or 6.0 mg, or placebo.

Evidence: "Histologic improvement in MASH with no worsening of fibrosis occurred in 47% of the 2.4-mg survodutide group, 62% of the 4.8-mg group, and 43% of the 6.0-mg group, compared with 14% in the placebo group. A decrease in liver fat content of at least 30% occurred in 63%, 67%, 57%, and 14% of participants, respectively. Improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively." — Sanyal AJ, et al. New England Journal of Medicine. 2024. DOI: 10.1056/NEJMoa2401755

The pattern matters: histologic MASH resolution rates of 47–62% with survodutide are higher than what GLP-1 monotherapy has produced in comparable trials, consistent with the mechanistic prediction that hepatic glucagon-receptor activation directly drives liver-fat oxidation.

SYNCHRONIZE-2 and the Cardiovascular Outcomes Trial

SYNCHRONIZE-2 is the Phase 3 trial in adults with obesity and type 2 diabetes — a population in which the GLP-1 class typically delivers 30–40% less weight loss than in non-diabetic cohorts.

Evidence: "SYNCHRONIZE-2 enrolled 1,206 participants with mean age 55.7 years, BMI 36.5 kg/m², and waist circumference 115.5 cm; 50.7% were female, with 36.2% from Europe, 32.8% from North America, and 22.3% from East Asia." — Wharton S, et al. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70263

The third pillar — SYNCHRONIZE-CVOT — is an event-driven cardiovascular safety trial that randomized 5,508 participants with obesity and either established cardiovascular disease, chronic kidney disease, or two or more cardiometabolic risk factors. The 5-point composite primary endpoint includes cardiovascular death, non-fatal MI, non-fatal stroke, ischemia-driven coronary revascularization, and heart failure events. A non-inferiority margin will determine whether survodutide is acceptable for chronic use in high-risk populations; superiority on heart failure events would be a regulatory differentiator, given that obesity-related heart failure with preserved ejection fraction is the fastest-growing HF phenotype.

Safety: Familiar GI Profile, Glucagon-Specific Watch-Outs

The Phase 2 obesity adverse-event profile mirrors what clinicians have come to expect from incretin-based drugs: predominantly gastrointestinal, dose-dependent, and concentrated during the titration window. In the MASH Phase 2, adverse events occurred in 91% of survodutide recipients versus 75% on placebo, with nausea (66% vs 23%), diarrhea (49% vs 23%), and vomiting (41% vs 4%) leading the list. Serious adverse events were similar between arms (8% vs 7%).

Three glucagon-specific signals warrant ongoing surveillance:

Heart rate: glucagon receptor activation can produce small dose-dependent increases in resting heart rate (typical magnitude: 3–6 bpm), comparable to what is observed with GLP-1 monotherapy
Glycemic neutrality: GLP-1 co-agonism is intended to neutralize glucagon's hyperglycemic effect; Phase 2 confirmed HbA1c reductions in non-diabetic participants and acceptable glycemic outcomes in diabetic cohorts, but vigilance during titration in T2D is appropriate
Hepatic safety: paradoxically, the MASH data argue for hepatic benefit rather than risk, but transaminase monitoring during early commercial use will be standard

The boxed-warning concerns common to the GLP-1 class — medullary thyroid carcinoma signal in rodents, pancreatitis surveillance, and gallbladder events — are expected to apply to survodutide as well based on the class label structure.

What This Means for Patients and Clinicians

Survodutide is unlikely to displace tirzepatide or CagriSema as the highest-magnitude weight-loss drug. Its 16.6% mean Phase 3 number is meaningful but lower than tirzepatide's 20.9% and CagriSema's 22.7%. The reason to care about it is mechanistic: it is the most advanced GLP-1/glucagon co-agonist in development and the cleanest test of whether engaging the glucagon axis adds clinical value beyond what GLP-1 alone provides.

The likely positioning, assuming Phase 3 completes successfully:

Patients with obesity plus MASH or significant hepatic steatosis — where the dual-receptor mechanism offers a metabolic rationale beyond weight loss alone
Patients with obesity plus heart failure — pending the SYNCHRONIZE-CVOT readout, glucagon receptor activation has plausible benefits on energy expenditure and visceral adiposity that may translate to HF outcomes
Patients who tolerate GLP-1s but plateau early — survodutide's distinct mechanism may offer a path past the GLP-1 weight-loss plateau

Regulatory submission timing will depend on full SYNCHRONIZE-1 data publication and the SYNCHRONIZE-2 readout. A realistic FDA decision window is late 2027 or 2028 — placing survodutide behind CagriSema (filed 2025, expected decision late 2026) and roughly contemporaneous with retatrutide.

Key Takeaways

Survodutide is a once-weekly subcutaneous dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma
Phase 3 SYNCHRONIZE-1 in non-diabetic obesity met its primary endpoint with 16.6% mean weight loss at 76 weeks vs 3.2% for placebo
Phase 2 MASH data showed up to 62% histologic resolution and ≥30% liver-fat reduction in two-thirds of participants
The mechanism is mechanistically distinct from semaglutide (GLP-1 only), tirzepatide (GLP-1 + GIP), and CagriSema (GLP-1 + amylin)
Safety profile is dominated by GI events typical of the incretin class; glucagon-specific monitoring focuses on heart rate and glycemia
Regulatory submission depends on completion of SYNCHRONIZE-2 and SYNCHRONIZE-CVOT, with a likely FDA decision in 2027–2028

References

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. DOI: 10.1016/S2213-8587(23)00356-X · PubMed
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. DOI: 10.1056/NEJMoa2401755 · PubMed
le Roux CW, Wharton S, Garvey WT, Vachtsevanou-Filippou D, Hennige AM, Wilding JPH, et al. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1). Diabetes Obes Metab. 2026;28(1):337-346. DOI: 10.1111/dom.70196 · PubMed
Wharton S, le Roux CW, Garvey WT, Vachtsevanou-Filippou D, Hennige AM, et al. Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026;28(2):1490-1498. DOI: 10.1111/dom.70263 · PubMed
Lincoff AM, Lingvay I, Wharton S, Pratley RE, le Roux CW, Buse JB, et al. Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Fail. 2024. DOI: 10.1016/j.jchf.2024.09.004 · PubMed
Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633. DOI: 10.1016/j.molmet.2022.101633 · PubMed
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183 · PubMed
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038 · PubMed

Last updated: 2026-05-01 Medical review: Dr. James Chen, MD, PhD, FACE